Clinical Trials in Denmark

• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha… Ended
  2024-511967-26-00 Phase III AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis) Janssen Cilag International
• A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants Wi… Ended
  2024-510727-19-00 Phase II Crohn's Disease (CD) AbbVie Deutschland GmbH & Co. KG
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar… Ended
  2023-508010-42-00 Phase III Homologous recombination deficiency advanced ovarian cancer Tesaro Inc.
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended
  2024-511235-10-00 Phase III Generalized mantle cell Lymphoma Klinikum der Universitaet Muenchen AöR
• HD21 Ended
  2024-518022-33-00 Phase III Advanced Stage of Hodgkin Lymphoma University Of Cologne
• "A study to learn how well the drug larotrectinib works in adults with different solid cancers with a change in the genes called NTRK fusion… Ended
  2022-502667-38-00 Phase II Solid tumors harboring NTRK fusion Bayer AG; Bayer Consumer Care AG
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 Phase III Subjects with resected adenocarcinoma or squamous cell carci… Bristol Myers Squibb International Corporation
• CheckMate 274 Ended
  2022-500630-29-00 Phase III Subjects with High Risk Invasive Urothelial Carcinoma Bristol-Myers Squibb Services Unlimited Company
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af… Ended
  2023-509137-39-00 Phase III Stage IB (T ≥ 4 cm), II and IIIA NSCLC Merck Sharp & Dohme LLC
• Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended
  2023-508067-70-00 Phase I/II Neoplasms by site Bristol Myers Squibb International Corporation
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended
  2023-504034-22-00 Phase III Chronic Lymphocytic Leukemia (CLL) F. Hoffmann-La Roche AG
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 Phase III Advanced or metastatic renal cell carcinoma Bristol Myers Squibb International Corporation
• BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended
  2024-518931-12-00 Phase II Neuroblastoma The University Of Birmingham
• Markers of bonestatus in Diabetes Mellitus patients (type 1 and type 2) and the effect of antiresorptive treatment on glycemic markers Ended
  2024-514148-99-00 Phase IV Diabetes Mellitus and Osteopenia/Osteoporosis Aalborg University Hospital
• Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended
  2023-506419-16-00 Phase III Advanced Classical Hodgkin Lymphoma Takeda Development Center Americas Inc.
• A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement b… Ended
  2024-514403-34-00 Phase I/II Late Metachromatic Leukodystrophy (MLD) Shire Human Genetic Therapies Inc.
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 Phase III Reversal of anticoagulation effect in patients on a FXa inhi… Astrazeneca AB
• Dapiglutide for the treatment of obesity (DREAM): a randomised, double-blind, placebo-controlled, investigator-initiated trial Ended
  2022-501649-54-01 Phase II Obesity Gentofte Hospital
• Cluster randomised trial of blood thinners Ended
  2022-502402-32-00 Phase IV Venous thromboembolism Rigshospitalet
• A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients with PK… Ended
  2022-502932-37-00 Phase III Phenylketonuria Synlogic Inc.
• A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended
  2023-503348-15-00 Phase I (FiH) Hodgkin lymphoma or non-Hodgkin lymphoma Genmab A/S
• European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatm… Ended
  2023-504282-23-00 Phase I Faecal incontinence University College London
• A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with… Ended
  2023-506240-16-00 Phase I/II Acute Myeloid Leukemia (AML) Sutro Biopharma Inc.
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended
  2023-506487-13-00 Phase III Hormone receptor-positive, her2-negative advanced/metastatic… Pfizer Inc.

Showing 1,489–1,512 of 1,524 trials